Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.71 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.71 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049924 | 0.95 | CYP4A11 (0.70) | CYP4A11CYP4F2CA12CA1CA2 | |
| SCHEMBL1701986 | 0.90 | CYP4A11 (0.58) | CYP4A11CYP4F2CA12CA1CA2 | |
| SCHEMBL15122388 | 0.90 | CYP4A11 (0.58) | CYP4A11CYP4F2CA12CA1CA2 | |
| SCHEMBL570964 | 0.88 | RARB (0.58) | CYP4A11CYP4F2CA12CA1CA2 | |
| SCHEMBL6389650 | 0.88 | CYP4A11 (0.64) | CYP4A11CYP4F2CA12CA1CA2 | |
| SCHEMBL6394479 | 0.87 | CA12 (0.56) | CYP4A11CYP4F2CA12CA1CA2 | |
| SCHEMBL6900234 | 0.87 | THRA (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6123675 | 0.87 | THRA (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12040863 | 0.87 | THRA (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6899814 | 0.87 | THRA (0.59) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209011-A1 | HETEROAROMATIC PHOSPHONIUM SALTS FOR TREATING CANCER | FLORATEK PHARMA S A (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240209011-A1 | HETEROAROMATIC PHOSPHONIUM SALTS FOR TREATING CANCER | FLORATEK PHARMA S A (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-4284517-A1 | HETEROAROMATIC PHOSPHONIUM SALTS FOR TREATING CANCER | Floratek Pharma SA (CH) | 2023-12-06 | — | — | EP | disclosed |
| US-20220411448-A1 | CHROMENE-4-ONE DERIVATIVES AS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MIMETICS | Floratek Pharma SA (CH) | 2022-12-29 | — | — | US | disclosed |
| US-20220411448-A1 | CHROMENE-4-ONE DERIVATIVES AS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MIMETICS | Floratek Pharma SA (CH) | 2022-12-29 | — | — | US | disclosed |
| WO-2022162029-A1 | HETEROAROMATIC PHOSPHONIUM SALTS FOR TREATING CANCER | FLORATEK PHARMA AG (CH) | 2022-08-04 | — | — | WO | disclosed |
| EP-4031538-A1 | CHROMENE-4-ONE DERIVATIVES AS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MIMETICS | Floratek Pharma AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021053205-A1 | CHROMENE-4-ONE DERIVATIVES AS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MIMETICS | FLORATEK PHARMA AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021053205-A1 | CHROMENE-4-ONE DERIVATIVES AS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MIMETICS | FLORATEK PHARMA AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-5093370-A | Useful prior to insertion of tracheotomy tube or discission | TOBISHI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1992-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209011-A1 | HETEROAROMATIC PHOSPHONIUM SALTS FOR TREATING CANCER | PIK3CA, TP53, CDK4 | CYP4A11 232/4885CYP4F2 552/4885CA12 1053/4885 |
| US-20220411448-A1 | CHROMENE-4-ONE DERIVATIVES AS BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) MIMETICS | BDNF, NTRK2, NGF | CYP4A11 316/4885CYP4F2 242/4885CA12 3749/4885 |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | AGTR1, AGTR2, AHR | CYP4A11 122/4885CYP4F2 113/4885CA12 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.